Login to Your Account

FDA Concerns Don't Alter Onyx's Carfilzomib Path

By Trista Morrison
Staff Writer

Tuesday, December 13, 2011
Onyx Pharmaceuticals Inc.'s plan to seek accelerated approval for multiple myeloma drug carfilzomib based on data from an open-label, single-arm Phase IIb trial was always risky – but it might have gotten a bit riskier over the weekend.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription